Oncology Biosimilars: A Primer for Clinicians

Learn about the integration of biosimilars into oncology care with this expert-authored module reviewing biosimilar fundamentals, the regulatory review process for biosimilars, current FDA-approved biosimilars, and key trial data on biosimilars in breast and lung cancers.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 20, 2020 Expired: April 19, 2021

Download these slides with expert recommendations on the approval and integration of oncology biosimilars for clinical practice.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Released: April 20, 2020